Holen Sie sich die Stockscreener-App
0.0739
37.11%
-0.0436
Schlusskurs vom Vortag:
$0.1175
Offen:
$0.0927
24-Stunden-Volumen:
39.74M
Relative Volume:
6.91
Marktkapitalisierung:
$2.31M
Einnahmen:
$680.00K
Nettoeinkommen (Verlust:
$-75.33M
KGV:
-0.0119
EPS:
-6.1898
Netto-Cashflow:
$-57.38M
1W Leistung:
-30.93%
1M Leistung:
-91.80%
6M Leistung:
-95.73%
1J Leistung:
-97.94%
1-Tages-Spanne:
$0.069
$0.0935
1-Wochen-Bereich:
$0.069
$0.1272
52-Wochen-Spanne:
$0.069
$3.95
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Firmenname
Bioxcel Therapeutics Inc
Sektor
Telefon
203-643-8060
Adresse
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
0.0739 | 2.31M | 680.00K | -75.33M | -57.38M | -6.1898 |
TAK
Takeda Pharmaceutical Co Adr
|
18.25 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.79 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.19 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.67 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
502.79 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-02-21 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-07-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-03-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-01 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-06 | Bestätigt | BofA Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-30 | Eingeleitet | Goldman | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-04 | Eingeleitet | Guggenheim | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
Alle ansehen
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
BioXcel Therapeutics (BTAIQ) Beta - Zacks Investment Research
BioXcel Therapeutics (BTAIQ) Eps Diluted (TTM) - Zacks Investment Research
All News for BTAIQ : BioXcel Therapeutics - Zacks Investment Research
BTAIQ: BioXcel TherapeuticsPrice & EPS Surprise - Zacks Investment Research
BioXcel Therapeutics, Inc. Revenue Breakdown – OTC:BTAIQ - TradingView
BTAIQ Stock Price Chart - eToro
Meet The Attorneys Guiding BioXcel Therapeutics' Ch.11 - Law360
Biotech filed for bankruptcy 11 weeks before its big FDA decision - thestreet.com
BioXcel Therapeutics, Inc.(OTCPK: BTAI.Q) dropped from NASDAQ Composite Index - marketscreener.com
Bioxcel Therapeutics Stock Price Forecast. Should You Buy BTAI? - StockInvest.us
symbol__ Stock Quote Price and Forecast - CNN
Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity? - finance.yahoo.com
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August - Benzinga
BioXcel Therapeutics, Inc. Share Price Live Today – NASDAQ:BTAI Stock Price, Chart, News, History - Upstox
BioXcel (BTAI) Stock News & Analysis - TechStock²
Case Summary: BioXcel Therapeutics Chapter 11 - Bondoro
$BioXcel Therapeutics (BTAI.US)$ only know .135-.115 it be like that - Moomoo
$BioXcel Therapeutics (BTAI.US)$ .1055 looking secured. investor terms liquidity zone looks full.🤔🧐 - Moomoo
BioXcel Therapeutics Company Profile & Introduction - Moomoo
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) dropped from S&P TMI Index - marketscreener.com
BioXcel Therapeutics Inc (NASDAQ: BTAI) Share Price, BTAI Stock News, BTAI Share Price & Updates - Kalkine
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) dropped from Russell 3000E Index - marketscreener.com
BioXcel Secures DIP Financing Amid Nasdaq Delisting Move - TipRanks
BioXcel Therapeutics Received Notice of Delisting - TradingView
BioXcel agrees to $77M DIP as Nasdaq delists - Stock Titan
Teva Bids $57.5 Million for BioXcel's Agitation Drug in Bankruptcy Auction - finance.biggo.com
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid - Yahoo Finance
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m - Yahoo Finance
BioXcel Stock Crashes 74.8% as Teva’s $57.5 Million Bid Meets Chapter 11 - TechStock²
BioXcel Therapeutics Files Chapter 11, Lines Up $125M Teva Asset Sale - ElevenFlo
Dow Gains 100 Points; Chicago PMI Falls In August - Sahm
Deal Dispatch: Carets Corp Explores Strategic Alternatives, nVent Electric Buys Maverick Power for $1.75 - Benzinga
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel - Pharmaceutical Executive
Teva Sinks on Bid to Buy BioXcel - Baystreet.ca
BioXcel Therapeutics Files Chapter 11, Agrees to Asset Sale With Teva - citybiz
Teva bids $57.5M for BioXcel’s agitation treatment asset By Investing.com - Investing.com UK
Teva Pharmaceutical Industries to Bid on BioXcel Therapeutics’ BXCL501 Dexmedetomidine Sublingual Film in Court-Supervised Sale Process - Quiver Quantitative
Teva Pharmaceutical Industries Ltd - Via Ritzau
BioXcel Therapeutics Picks Teva as Stalking Horse in $57.5M Asset Sale, Up to $87.5M in Milestones - TradingView
BTAI Looks 33.2% Overvalued on GF Value™ Amid Bankruptcy Filing - GuruFocus
L'azienda biofarmaceutica BioXcel Therapeutics presenta istanza di fallimento negli Stati Uniti - TradingView
Motion for Joint Administration Filed by BioXcel Therapeutics, Inc. - marketscreener.com
BioXcel Therapeutics Amends Credit Agreement Amid Liquidity Strain - The Globe and Mail
BioXcel Therapeutics Adds $1.25 Million Oaktree Term Loans, Wins Liquidity Covenant Relief - TradingView
Bioxcel Therapeutics Enters Fourteenth Amendment To Credit Agreement On August 24, 2026 - TradingView
ARMISTICE CAPITAL, LLC Reduces BioXcel Therapeutics Inc (BTAI) S - GuruFocus
BioXcel Therapeutics Faces August 21 Oaktree Transaction Deadline As $13.8 Million Cash Funds Operations Only Through August - Pulse 2.0
BioXcel (BTAI) Session Check: Ends Down by 11.01% at $0.79; Chart Reference: the $0.75 to $0.83 Range Remains in Focus on the DayCatalyst Driven Stocks - vinanet.vn
BioXcel Shareholder Notice - TMX Newsfile
BioXcel Therapeutics earnings missed by $0.07, revenue fell short of estimates - Investing.com
BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares - Stock Titan
Finanzdaten der Bioxcel Therapeutics Inc-Aktie (BTAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioxcel Therapeutics Inc-Aktie (BTAI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rodriguez Javier | See Remarks |
May 20 '26 |
Sale |
1.08 |
6,560 |
7,111 |
26,803 |
| Steinhart Richard I | Chief Financial Officer |
May 20 '26 |
Sale |
1.08 |
6,845 |
7,427 |
26,300 |
| Mehta Vimal | CEO and President |
May 20 '26 |
Sale |
1.09 |
19,419 |
21,108 |
69,598 |
0.33%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):